Plné znění - 2/2008 Sb. m. s.

Ministerstvo xxxxxxxxxxxx xxxx sděluje, xx xxx 16. xxxxxxxxx 2007 xxxx xxxxxxxxxx xxxxxxxxx XXXXXX, xxxxxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu¹⁾, xxxxxxxx schválení xxxxxx xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx.

Xxxxxxx I xxxxxxxxx x xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2008 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx Xxxxxxx I x xxxxxxxx přestává xxxxxx Příloha I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu xx xxxxx pro xxx 2007, xxxxxxxxx xxx x. 59/2007 Xx. x. x.

Xxxxxxxx znění Xxxxxxx X x její xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

x. Exogenní * XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-androst-1-en-3,17-dion); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); bolasteron; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-xxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-nor-17α-pregn-4-en-17-ol); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolom; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-dimetyl-5α-androstan-3-on-17β-ol); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); methyltestosteron; xxxxxxxxx; nandrolon; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prostanozol ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

b. Xxxxxxxxx ** AAS:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx x xxxxxxx:

5α-xxxxxxxxx-3α,17α-xxxx xxxxxxx-5-xx-3β,17α-xxxx

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-xxxxxxxxx-3β,17β-xxxx xxx-xxxxxxxxxxxxxxxxxx

xxxxxxx-4-xx-3α,17α-xxxx 3α-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-5-xx-3β,17α-xxxx 19-xxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17α-xxxx 19-xxxxxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17β-xxxx

X xxxxxxxxx, kdy může xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx, xxxx xx mít xx xx, xx Xxxxxx obsahuje tuto Xxxxxxxxx látku a xxxx xxxxxx xxxxxxxxx Xxxxxxxxx laboratorní nález, xxxx xx xxxxxxxxxxx Xxxxxxxx látky xxxx xxxxxx metabolitů nebo xxxxxxxxxxx x/xxxx když xx xxxxxxxx xxxx xxxxxxxxx xxxxx ve Xxxxxx Xxxxxxxxx xxxxxxxx xxxxxxxxx od xxxxxxx xxxxxx, xxxxx xx xxxxxxxx xxxxxxxxx x xxxx xxx, xx xxxxxxxxxx xxxxxxxx endogenní xxxxxxxx. Xxxxxx se xxx za to, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx v xxxxxxx xxxxxxx, xxxxx Xxxxxxxxx xxxxxxx, xx xx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx xxxx xxxxxxxxxx x/xxxx xxxxxxxxx xxxxx xx Vzorku Xxxxxxxxx xxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxxxxx xxxxxx.

Xxxx xx mít za xx, xx Xxxxxx Xxxxxxxxx obsahuje Zakázanou xxxxx x xxxxxxxxx xxxxxxx Pozitivní laboratorní xxxxx xx xxxxx xxxxxxxxx a xxx xxxxxxxxx xxxxxxxxxxx, xxxxx xxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx, že xx Xxxxxxxx látka xxxxxxxxxx původu. V xxxxxxx xxxxxxx není xxxxx xxxxxxxx další xxxxxxx.

Xxxx xx xxxxxxx výsledku analýzy xxxxxxxx neodchylují od xxxxxxx xxxxxx, xxxxx xx xxxxxxxx xxxxxxxxx x xxxx x xxxxx spolehlivá analytická xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx xxxxx, ale xxxxxxxx xxxxxx použití Xxxxxxxx xxxxx, jako xxxx. xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, nebo když xxxxxxxxx xxxxxxxxx poměr X/X vyšší xxx xxxxx (4) xx xxxxx (1) x xxxxx spolehlivá analytická xxxxxx (např. IRMS) xxxxxxxxxxx xxxxxxxx xxxxx xxxxx, xxxxxxx xxxxxxxxx Xxxxxxxxxxxxx organizace xxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxxxxx xxxxx.

Xx-xx xxxxxxxxxx xxxxxx xxxxx xxxxxxx, pak xxxxxxxx xxxx laboratoří xxxxxx xxxx neobvyklý x ne jako xxxxxxxxx. Xxxxx xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxxxx analytické xxxxxx (xxxx. IRMS) xxxxxxxx xxxxx Zakázané xxxxx, xxxx xxxxx xxxxxxxx xxxxx šetření, a xxxx se xxx xx to, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx. Xxxxx nebyla xxxxxxx spolehlivá xxxxxxxxxx xxxxxx (xxxx. XXXX) x xxxxxx x xxxxxxxxx xxxxxxxxx 3 xxxxxxxxx xxxxx, xxxx xxxxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx tím, xx xxxx příslušnou Antidopingovou xxxxxxxxxx v xxxxxxxxxxxxx 3 měsících xxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, který xxxxxxxxxx xxxx xxxxxxxxxxxxxx xxxxxx, xxxx xxxxxx xxxx neobvyklý. Xxxxx xxxxxxxxxxxxxx profil Xxxxxxxxx, xxxxxxxx xxxxxxxxxx xxxxx, xxxx fyziologicky xxxxxxxx, xxxx xx xxx xxxxxxxxx xx Pozitivní xxxxxxxxxxx nález.

V xxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxx x xxxx trvale xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxx xxxxxx xxxxxxxxxxxxx (ng/ml). Xxxxx xxxxxxxxx xxxxxx xxxxx nahlásila a xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. IRMS) xxxxxxxxxxx exogenní xxxxx Xxxxxxxx xxxxx, může xxx xxxxxxxxx xxxxx xxxxxxx provedením xxxxxxxxxx xxxxx (xxxxxxxxxx xxxxx).

Xxxxx xxxxxxxxx xxxxxxxxx Xxxxxxxxx laboratorní xxxxx 19-xxxxxxxxxxxxxxx, xxxx xx xx xxxxxxxxx za xxxxxxx x přesvědčivý xxxxx exogenního původu Xxxxxxxx látky. X xxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx xxxxx xxxxxxx.

X případě, xx Xxxxxxxxx xxxxxx xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxxx, xxxx se xxx xx to, xx Vzorek Xxxxxxxxx xxxxxxxx Zakázanou xxxxx.

2. Ostatní xxxxxxxxxx xxxxx, zahrnující:

Xxxxxxxxxxx, xxxxxxxxxx modulátory androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

X2. XXXXXXX A XXXXXXXX XXXXX

Následující látky x jejich xxxxxxxxxx xxxxxxx xxxx zakázány:

1. Erytropoetin (XXX);

2. Xxxxxxx xxxxxx (xXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxxx (xxxx. XXX-1), xxxxxxxxxx růstové xxxxxxx (XXX);

3. Xxxxxxxxxxxxx (např. XX, xXX), xxxxxxxx xxx x xxxx;

4. Xxxxxxxx;

5. Xxxxxxxxxxxxxx

x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxx Xxxxxxxxx xxxxxx prokázat, xx koncentrace xxxx xxxxxxxxx xxxxxxxxxxxxx xx xxxxxxxxxxxx xxxxxx, bude xx mít xx xx, že Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx (xxx je uvedeno xxxx) v případech, xxx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx xx xxxxxxxxxx x/xxxx xxxxxxxxx xxxxxx xx Vzorku Sportovce xxxxxxx xxxxxxxx hodnoty xxxxxxxx zjištěné u xxxx xxx, xx xxxxxxxxxxxx normální xxxxxxxxx xxxxxxxx.

Pokud xxxxxxxxx xxxxxxxxx, xx xxxxx xxxxxxxxxx xxxxxxxxxx metody, xx Xxxxxxxx látka xx xxxxxxxxxx xxxxxx, xxxx se xxx xx to, xx Xxxxxx obsahuje Xxxxxxxxx xxxxx x xxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx.

X3. XXXX-2 XXXXXXXX

Xxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxxx X- x X-xxxxxxx jsou xxxxxxxx.

Xxxxxxxx xxxx formoterol, xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxx, pro xxxxx xx xxx xxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxx.

X xxxx xxxx udělena xxxxxxxx xxxxx terapeutické xxxxxxx, xxxx xxxxx xxxxxxxxxxx (volný plus xxxxxxxxxx) vyšší xxx 1000 nanogramů v 1 xxxxxxxxx xxxx xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx xxxxxxxxx, že xxxxxxxxxx výsledek xxx xxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxx v inhalaci.

X4. ANTAGONISTÉ X MODULÁTORY XXXXXXX

Xxxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Inhibitory xxxxxxxx, zahrnující:

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxx:

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

4. Xxxxx modifikující funkce xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

X5. XXXXXXXXX X XXXXXXX XXXXXXXXX LÁTKY

Xxxxxxxxx látky xxxx zakázané. Xxxxxxxx:

Xxxxxxxxx*, xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxx-xxxxxxxxx (např. xxxxxxxxxx, dutasterid), xxxxxxxxxxxxxxx (xxxx. albumin, dextran, xxxxxxxxxxxxxxxxx) x xxxxx xxxxx x podobnými xxxxxxxxxxxx xxxxxx.

Diuretika xxxxxxxx:

Acetazolamid, xxxxxxxx, xxxxxxxxx, furosemid, chlortalidon, xxxxxxxxx, kanrenon, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky (xxxxx xxxxxxxxxxxx, který xxxx xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx xxxx xxxxxx, xxxxx xxx Xxxxxxxxx xxxxxxxx xxxxxxxxx ve xxxxxxx s xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxx Xxxxxxxx látky (xxxxx).

X1. XXXXXXXXX PŘENOSU XXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

M3. XXXXXX XXXXXX

Xxxxxxxxxxxxxx xxxxxxx buněk, genů, xxxxxxxx xxxxxxxx, xxxx xxxxxxxxxx exprese genů, xxxxx mají schopnost xxxxxx xxxxxxxxx výkon, xx xxxxxxxx.

X6. XXXXXXXXXXX

Všechna xxxxxxxxxxx (včetně xxxx xxxxxx xxxxxxxxxx optických (X- x X-) xxxxxxx) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x případě xxxxxx xxxxxxxx xxxxx x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx rok 2008.

Xxxxxxxxxxx zahrnují:

Xxxxxxxxx, xxxxxxxxx**, xxxxxxxxxx, amfetaminil, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx****, etamivan, xxxxxxxxx, ethylamfetamin, famprofazon, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-fenylpiracetam (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxx***, klobenzorex, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, levmetamfetamin, xxxxxxxxx, mefentermin, xxxxxxxxxxxx, xxxxxxxxxxxx (X-), xxxxxxxxxxxx****, xxxxxxxxxxxxxxxxxxxxxx, methylendioxymetamfetamin, xxxxxxxxxxxxx, xxxxxxxx, modafinil, niketamid, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, x-xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, tuaminoheptan x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

Xxxxxxxxxxxx neuvedené xxxxxxxx xxxx xxxxxxxx x xxxxx xxxxxx xxxx xxxxxxxxxx xx specifickou xxxxx xxxxx, pokud Xxxxxxxxx prokáže, xx xxxx xxxxxxxxx xxxxxxxxxx x xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx, xxxx xx x xxx menší xxxxxxxxxxxxxxx, xx xxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxx xxxxx.

S7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx zakázaná:

Buprenorfin, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, pentazocin, xxxxxxx.

S8. XXXXXXXXXXX

Xxxxxxxxxxx (xxxx. xxxxx, marihuana) xxxx xxxxxxxx.

S9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, rektálně, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx. Xxxxxx užití vyžaduje xxxxxxxxxxxxx výjimku.

Xxxx xxxxxxx injekční xxxxxxxx (xxxxxxxxxxxx, xx okolí xxxxxx, do okolí xxxxxx, xxxxxxxxxx, xx xxxx) x xxxxxxxxx xxxxxxxx vyžadují xxxxxxxxx xxxxxxxxxxxxx xxxxxxx s xxxxxxxx xxxx uvedených.

Xxxxxxx xxxxxxxxx xxxxxxxx xx potíže xxxxx (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), ušní, xxxxx, xxxx, xxxxxx xxxxx xxxxxxx otvoru, xxxxxxxx úst a xxxxx xxxxxx xxxxxxxx x xxxxxxxxxx žádnou xxxxx terapeutické xxxxxxx.

X1. XXXXXXX

Alkohol (xxxxxx) xx xxxxxxxx xxxxx Xxx xxxxxxx v xxxxxxxxxxxxx sportech. Xxxxxxx xx bude xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx pro xxxxxxxx xxxxxxxxxxx xxxxxxxx (hematologická xxxxxxx) je xxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (XXX) (0.10 x/x)

∙ Xxxxxx (WKF) (0.10 x/x)

∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX) (0.20 x/x)

∙ Lukostřelba (FITA, XXX) (0.10 x/x)

∙ Xxxxxxx pětiboj (XXXX) jen xxx xxxxxxxxxx xx xxxxxxxx (0.10 g/l)

∙ Xxxxxxxxxxx xxxxx (XXX) (0.10 g/l)

∙ Xxxxx xxxxxxxxxx (XXX) (0.30 x/x)

∙ Kuželky (XXX) (0.10 g/l)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx zakázány xxxxx Xxx xxxxxxx x xxxxxxxxxxxxx sportech.

∙ Automobilový xxxxx (XXX)

∙ Billiard (XXXX)

∙ Xxxx (XXXX)

∙ Xxxxx (XXX)

∙ Curling (XXX)

∙ Gymnastika (XXX)

∙ Xxxxxxxx (XXXX) - "xxxxx xxxx" - jen xxxxxxxxxxx

∙ Kuželky (XXX)

∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)

∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x snowboard X-xxxxx x "xxx air"

∙ Xxxxxxx xxxxxxx (XXXX) - jen xxxxxxxxxx xx xxxxxxxx

∙ Xxxxxxxxxxx xxxxx (XXX)

∙ Petanque x xxxxxxx sporty (XXXX, IPC "xxxxx")

∙ Střelba (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

∙ Xxxxx xxxxxxxxxx (XXX)

∙ Zápas (XXXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, timolol, xxx xx x xxxxxxxx xxxxx na xx

"Xxxxxxxxxx látky"* xxxx vyjmenovány xxxx:

∙ Xxxxxxx Beta-2 xxxxxxxx v xxxxxxxx, xxxxx salbutamolu (volného xxxx xxxxxxxxxxx) při xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx x xxxxxxxxxxxx (xxxxxxx xx skupině S 1.2 Xxxxxxx xxxxxxxxxx xxxxx);

∙ Xxxxxxxxxx xxxx-xxxxxxxxx, probenecid;

∙ Xxxxx, kropropamid, xxxxxxxxxx, xxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, isomethepten, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, niketamid, xxxxxxxxxxx, xxxxxxxxx, ortetamin, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxx X6, xxx která Xxxxxxxxx prokáže, xx xxxxxxx xxxxxxxx popsané x xxxxxx S6;

∙ Xxxxxxxxxxx;

∙ Xxxxxxx Xxxxxxxxxxxxxxxxxxxx;

∙ Xxxxxxx;

∙ Xxxxxxx Xxxx-xxxxxxxxx.

*"X Seznamu xxxxx být xxxxxxxxxxx xxxxxxxxxx látky, xxxxx xxxxxxxx xxxxxxxx neúmyslné xxxxxxxx xxxxxxxxxxxxxxx pravidel, xxxxxxx jsou xxxxxxxxx xxxxxxxx x běžných xxxxxxxxx xxxxxxxxxxx, xxxx x xxxxx xx xxxxx xxxxxxxxxxxxxxx, xx xxxxx xxxxxxx xxxxxxxx xxxx dopingová xxxxxxx." Xxxxxxxx antidopingového pravidla xxxxxxxxxx takovéto xxxxx xxxx znamenat snížený xxxxxx xx předpokladu, xx "...Xxxxxxxxx může xxxxx xxxxxxxx, že Xxxxxxx specifické xxxxx xxxxxx zamýšleno xx xxxxxxx xxxxxxxxxxx xxxxxx...".

Xxxxxx xxxxxxx č. 2/2008 Xx. m. x. xxxxx xxxxxxxxx xxxx 31.1.2008.

Xxxxxx xxxxxxx č. 2/2008 Sb. x. x. xxx zrušen xxxxxxx xxxxxxxxx č. 8/2009 Sb. m. s. x účinností xx 7.2.2009.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx derogační xxxxx shora uvedeného xxxxxxxx xxxxxxxx.